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Abstract
Vaccinia virus (VACV) protein N1 is an intracellular virulence factor and belongs to a family of VACV B-cell lymphoma (Bcl)-2-
like proteins whose members inhibit apoptosis or activation of pro-inflammatory transcription factors, such as interferon
(IFN) regulatory factor-3 (IRF-3) and nuclear factor-kB (NF-kB). Unusually, N1 inhibits both apoptosis and NF-kB activation.
To understand how N1 exerts these different functions, we have mutated residues in the Bcl-2-like surface groove and at the
interface used to form N1 homodimers. Mutagenesis of the surface groove abolished only the N1 anti-apoptotic activity and
protein crystallography showed these mutants differed from wild-type N1 only at the site of mutation. Conversely,
mutagenesis of the dimer interface converted N1 to a monomer and affected only inhibition of NF-kB activation.
Collectively, these data show that N1 inhibits pro-inflammatory and pro-apoptotic signalling using independent surfaces of
the protein. To determine the relative contribution of each activity to virus virulence, mutant N1 alleles were introduced into
a VACV strain lacking N1 and the virulence of these viruses was analysed after intradermal and intranasal inoculation in
mice. In both models, VACV containing a mutant N1 unable to inhibit apoptosis had similar virulence to wild-type virus,
whereas VACV containing a mutant N1 impaired for NF-kB inhibition induced an attenuated infection similar to that of the
N1-deleted virus. This indicates that anti-apoptotic activity of N1 does not drive virulence in these in vivo models, and
highlights the importance of pro-inflammatory signalling in the immune response against viral infections.
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Introduction
Viral infections are sensed by pattern recognition receptors that
activate the innate immune system which precedes the develop-
ment of an adaptive immune response. The strength of this initial
innate immune activation determines the quality of the acquired
immune responses and, consequently, the progression and
outcome of the infection. Vaccinia virus (VACV), the smallpox
vaccine, has a large double-stranded DNA genome of about
190 kb. Approximately half of the genes are non-essential for virus
replication and many of these modulate the innate immune
response [1,2]. VACV protein N1 is one of these immune
modulators. N1 is a dimeric cytosolic protein expressed early
during infection [3] that contributes to viral virulence [3–5]. It
belongs to a family of VACV proteins displaying a B cell
lymphoma (Bcl)-2-like structural fold whose members inhibit
apoptosis or activation of pro-inflammatory transcription factors
[6–12]. N1, however, is unusual in that it inhibits both pro-
apoptotic and pro-inflammatory signalling [7,8,13].
Pro-inflammatory signalling in epithelial cells is controlled by
transcription factors such as IRF-3 and NF-kB. The NF-kB
complex is a major regulator of the host antiviral innate immunity
and consists of a family of dimeric transcription factors retained in
the cytoplasm of resting cells by association with NF-kB inhibitory
proteins (IkB) [14,15]. Binding of cytokines interleukin-1 (IL-1) or
tumour necrosis factor-a (TNFa) to their receptors or engagement
of Toll-like receptors (TLRs) by their ligands leads to activation of
signalling pathways that converge at the IkB kinase (IKK)
complex. Once activated, the IKK complex then phosphorylates
IkB causing its ubiquitination and degradation by the proteasome.
PLoS Pathogens | www.plospathogens.org 1 December 2011 | Volume 7 | Issue 12 | e1002430Consequently, NF-kB is released and translocated into the nucleus
where it induces transcription of NF-kB-dependent genes.
Activation of NF-kB via the IL-1 receptor and TLRs requires
the recruitment of the adaptor proteins myeloid differentiation
factor 88 (MyD88) and TNF-receptor-associated factor 6
(TRAF6), whereas activation via the TNF receptor requires the
kinase receptor interacting protein (RIP) and TRAF2 [14,16]. N1
was reported to prevent activation of the transcription factors NF-
kB and IRF-3 deriving from a variety of stimuli by targeting
several components of the IKK and the TANK-binding kinase 1
(TBK1) complexes [13]. Other studies have also shown inhibition
of NF-kB signalling by N1, but did not find interactions between
N1 and components of the IKK or TBK1 complexes [7–9] and
consequently the mechanism employed by N1 to prevent NF-kB
activation remains unclear.
Apoptosis is an irreversible cascade of biochemical events
orchestrated by caspase proteases that culminates in cell death and
represents a potent mechanism that aids elimination of virus-
infected cells [17]. Consequently, viruses have developed strategies
to subvert apoptotic signalling and facilitate completion of their
replication cycle [18,19], including expression of Bcl-2 like
proteins from Kaposi sarcoma-associated herpesvirus [20,21],
Epstein-Barr virus (BHRF1) [22–24], c-herpesvirus 68 (vBcl-2)
[25,26], myxoma virus (M11) [27–30] and VACV (F1 and N1)
[7,8,31,32,33,34,35]. A central feature of apoptosis is mitochon-
drial outer membrane permeabilization (MOMP) that leads to the
release of cytochrome c to the cytosol and formation of the caspase
activation platform known as the apoptosome. The Bcl-2 family of
proteins regulates MOMP by complex protein-protein interactions
between pro-apoptotic and anti-apoptotic members of the family
[36,37]. Anti-apoptotic proteins (Bcl-2, Bcl-xL, Bcl-w) contain four
Bcl-2 homology motifs (BH1-4) and are generally integrated in the
outer mitochondrial membrane (OMM). They prevent apoptosis
by binding the BH3 motif of the pro-apoptotic Bcl-2 proteins. Pro-
apoptotic Bcl-2 proteins are divided into the effector proteins (Bax,
Bak), which homo-oligomerise and insert into the OMM to
promote MOMP, and the BH3-only proteins, which either bind
only the anti-apoptotic members (Bad, Noxa) or bind these as well
as the pro-apoptotic effector proteins (Bid, Bim) [36,38].
The crystal structure of N1 identified a groove similar to those
of cellular anti-apoptotic Bcl-2 proteins [6,8]. However, N1 lacks
the C-terminal helix that regulates access to the binding groove
and so is a constitutively ‘active’ anti-apoptotic protein [8].
Consistent with this, N1 interacts with endogenous Bad, Bax and
Bid and protects cells from staurosporine (STS)-induced apoptosis
[8]. Moreover, while a similar Bcl-2 fold is observed for other
VACV proteins B14, A52 and K7 that are also inhibitors of NF-
kB, neither a BH3-binding groove nor an anti-apoptotic activity
are observed in these proteins [7,39]. N1 is therefore unusual in its
dual ability to modulate both apoptosis and inflammatory
signalling.
In this study specific mutations were introduced into N1 that
eliminate either its ability to prevent apoptosis or block NF-kB
activation. N1 proteins that display only one of the two functions
have been structurally and biophysically characterized, and
recombinant VACV expressing these proteins were generated
and their virulence was assessed in murine models. Data presented
show that inhibition of apoptosis and NF-kB activation are
mediated by different surfaces of the N1 protein and that mutation
of N1 so that it no longer inhibits apoptosis did not affect
virulence, whereas inhibition of pro-inflammatory signalling was
important for virulence.
Results
Mutagenesis of vaccinia virus protein N1
To understand how N1 interferes with pro-apoptotic and pro-
inflammatory signalling, we introduced point mutations in N1
based on its crystal structure. N1 contains a surface groove
predicted to bind BH3 peptides [6,8]. By analogy with VACV
proteins A52 and B14, which have the surface groove filled by
bulky amino acid residues and do not inhibit apoptosis [7], we
introduced the bulky residue tyrosine at positions R58, Q61 and
R71 in an attempt to ‘fill’ the N1 groove and thereby exclude
BH3-peptide binding (Figure 1). Mutations were also introduced at
the hydrophobic surface that mediates formation of N1 dimers.
The VACV Bcl-2-like proteins N1, B14 and A52 all form dimers
via a common surface comprising alpha helices 1 and 6 (the ‘1–6
face’) [7,8,11,39]. This same surface is also used by the VACV Bcl-
2 family protein K7 to bind the host-cell protein DDX3 [7,8,39].
To determine whether dimer formation via this surface is
important for N1 function, a hydrophobic to polar mutation
(I6E) was introduced (Figure 1).
Structures of wild-type and groove-filling mutant N1
To determine if the point mutations introduced in N1 generated
unanticipated structural changes, R58Y, Q61Y and R71Y N1
were expressed in bacteria, purified to homogeneity and their
structures determined at 3.0–3.1 A ˚ resolution (Table S1). All three
mutants crystallized in the same space group as wild-type N1 [8]
and the overall structures of all three closely resembled the wild-
type protein (0.21–0.39 A ˚ r.m.s. deviation over 108 Ca atoms)
(Figure 2A). In each case the point mutation could be readily
identified and the mutated residues are shown in final refined
structures in Figure 2B. For both the R58Y and Q61Y mutants,
the tyrosine residue protruded into the groove in a manner likely
to reduce BH3 peptide binding. However, in the R71Y mutant,
the tyrosine lay along the bottom of the groove, not protruding
upwards like the original arginine side chain and so the groove
remained ‘‘open’’. In all cases the mutated side chains were the
only significant structural difference between wild-type and
mutant N1. Unfortunately I6E N1 proved refractory to all
crystallization attempts.
Author Summary
Viruses have multiple strategies to escape the host
immune system. These include proteins to inhibit cellular
signalling pathways promoting an inflammatory response,
and others that prevent programmed cell death (apopto-
sis), allowing completion of the virus replication cycle. This
paper concerns the vaccinia virus (VACV) protein N1, which
forms homodimers and blocks activation of both apopto-
sis and the pro-inflammatory NF-kB transcription factor. By
introducing mutations in N1, we demonstrate that these
functions are mediated by different surfaces of the protein.
Biochemical and structural analysis of these mutants
demonstrates that the anti-apoptotic activity of N1 relies
on a hydrophobic groove on the surface of the protein and
that the anti-NF-kB activity requires an intact dimer
interface. Recombinant VACVs expressing the mutant N1
proteins were made to investigate the contributions of the
different properties of N1 to virulence. The results showed
that the anti-NF-kB activity of N1, rather than the N1-
mediated inhibition of apoptosis, is the major contributor
to virulence. This underlines the central role of pro-
inflammatory signalling in the host immune response
against viral infections.
N1 Regulation of Innate Immunity
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mutants
The ability of the N1 mutants to form dimers was investigated
next. Plasmids encoding FLAG-tagged wild-type (WT) or mutant
N1 were co-transfected into HEK 293T cells with HA-tagged WT
N1. FLAG- and HA-tagged mutant N1 proteins were expressed to
the same level as WT N1 (Figure 3A). After immunoprecipitation
(IP) with an anti-FLAG antibody, the presence of HA-tagged N1
was analysed by immunoblotting with anti-HA antibody. While
the surface groove mutants (R58Y, Q61Y, R71Y) and WT N1
interacted efficiently with HA-tagged N1, the I6E mutant did not
(Figure 3A). Similar results were obtained by LUMIER after co-
transfection of the FLAG-tagged N1 alleles together with WT N1
fused with renilla luciferase (Rluc.N1) (Figure 3B). After measuring
the luciferase activity in the cell lysates and the immunoprecip-
itates using anti-FLAG monoclonal antibody, a ratio for each
condition was calculated and compared to mock controls. The I6E
mutant was the only protein unable to interact with Rluc.N1. To
quantify the extent of self-association we measured the molar mass
of WT and mutant N1 directly by subjecting purified proteins
(Figure 3C) to size-exclusion chromatography with multi-angle
light scattering (SEC-MALS). While WT N1 and the groove-filling
mutants (R58Y, Q61Y, R71Y) were all dimeric, the I6E mutant
was almost exclusively monomeric (Figure 3D). The ability of the
mutant N1 proteins to dimerise during viral infection was also
investigated using an inducible cell line expressing TAP-tagged
WT N1 and VACV recombinant viruses expressing mutant N1
(see below for virus generation and characterisation). Cells were
induced to express N1 by addition of doxycycline and subse-
quently were infected with the viruses expressing mutant N1
proteins (Figure 3E). After IP with anti-FLAG, immunoprecipi-
tates were immunoblotted to reveal the presence of the
immunoprecipitated FLAG-tagged N1 from the cell line and its
association with untagged N1 protein from the viruses. WT,
mutant R58Y and R71Y N1 proteins expressed during viral
infection retained ability to dimerise, whereas mutant I6E N1
protein did not. Taken together, these results show that I6E N1
does not self-associate either in vitro or in mammalian cells.
Functional characterization of mutant N1
The anti-apoptotic ability of the N1 mutants was analysed next.
FLAG-tagged plasmids expressing WT and mutant N1 were co-
transfected in HeLa cells together with a CD20 surface marker.
Mutant and WT proteins showed a comparable expression in
HeLa cells (Figure S1), as previously observed for HEK 293T cells.
Cells were treated with STS and the permeabilization of the
mitochondrial membrane was measured in CD20 positive cells.
Introduction of the groove-filling mutations R58Y and Q61Y
abolished the ability of N1 to prevent apoptosis, while mutants
R71Y and I6E inhibited STS-induced apoptosis as strongly as WT
N1 (Figure 4A). As the mutated side chains were the only
significant structural difference between wild-type N1 and the
mutants that failed to inhibit apoptosis, these data demonstrate
that the surface groove determines the ability of N1 to inhibit
Figure 1. Mutagenesis of vaccinia virus protein N1. The structure of an N1 homodimer is shown as a molecular surface, the two molecules
being coloured white and grey. Residues at the dimerisation interface of each molecule are highlighted in blue. A model of a BH3 peptide (light green
helix) bound to N1, generated by superposition of N1 onto the M11:Bak BH3 peptide complex (PDB ID 2JBY), is shown (right). Mutations introduced
in the BH3-peptide binding groove (lower right) and dimerisation interface (lower left) are shown in electric blue.
doi:10.1371/journal.ppat.1002430.g001
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apoptosis.
We next sought to determine the ability of the N1 mutants to
interfere with NF-kB signalling. HEK 293T cells were transfected
with an NF-kB-luciferase responsive reporter alongside the
different FLAG-tagged N1 mutants and these cells were stimulated
subsequently with IL-1b. Expression of WT N1 decreased NF-kB
activation significantly, as did expression of the groove mutants
(Figure 4B). However, expression of the I6E mutant did not inhibit
NF-kB-induced gene expression significantly. NF-kB activation
was also induced by over-expression of TRAF6 and under these
conditions the different FLAG-tagged N1 mutants gave similar
results (Figure 4C). These data show that I6E N1 is impaired for
inhibition of NF-kB activation, and demonstrates that mutagenesis
in the BH3-binding cleft does not interfere with the ability of N1 to
inhibit inflammatory signalling. These data might indicate that
either dimer formation is needed for the ability of N1 to inhibit
NF-kB activation, or that the dimer interface is needed for binding
of unknown signalling molecules that activate NF-kB and this, as
well as dimer formation, is ablated by the I6E mutation.
Immunoprecipitation of pro-apoptotic Bcl-2 proteins
with mutant N1 proteins
Previously, N1 was shown to interact with cellular pro-apoptotic
Bcl-2 proteins [6,8]. To determine whether the loss of anti-
apoptotic activity of groove-filling N1 mutants R58Y and Q61Y
correlated with loss of binding to pro-apoptotic Bcl-2 proteins,
immunoprecipitation assays were carried out. HA-tagged Bad was
co-expressed in 293T cells together with FLAG-tagged mutant N1
proteins and after IP with anti-FLAG antibody, association with
Bad was revealed by anti-HA immunoblotting (Figure 5A). VACV
protein A52 was used as negative control because the surface
groove of this protein is occluded and A52 is not able to inhibit
apoptosis [7]. In this assay, both WT and I6E mutant N1, where
the groove is intact, interacted with HA-tagged Bad, whereas
groove-filling Q61Y mutant N1, as well as A52, failed to
immunoprecipitate with Bad. Interestingly, groove mutant R71Y
which retains the ability to prevent STS-mediated apoptosis,
associated with Bad. Likewise, when untagged Bid was co-
expressed in cells, Q61Y mutant was unable to interact with
Bid, whereas R71Y mutant, as well as WT N1, still immunopre-
cipitated Bid (Figure 5B). Similar results were obtained with the
use of VACV recombinant viruses expressing these mutant
proteins (data not shown). The interaction of WT and mutant
N1 proteins with Bax was also investigated, but under the
conditions tested the level of interaction with Bax was too low to
enable the binding of the mutant N1 protein to be determined.
Collectively, these results indicate that mutations in the N1 groove
that inhibited anti-apoptotic activity correlate with an inability to
interact with cellular pro-apoptotic Bcl-2 proteins.
Mitochondrial targeting of N1 abolishes its anti-
apoptotic function
Cellular anti-apoptotic Bcl-2 proteins, like Bcl-xL and Bcl-w,
reside in the OMM where they prevent cell death by binding BH3
peptides of pro-apoptotic Bcl-2 family proteins [36]. In contrast
VACV protein N1 is cytosolic without localisation to the
mitochondrion or other organelles [3]. To address whether the
ability of N1 to interfere with pro-apoptotic signalling could be
enhanced if it were present on mitochondria, the last 38 residues of
Figure 2. Structures of wild-type and groove-filling mutant N1. (A) The structures of wild-type and mutant N1 are shown as superposed Ca
traces with two orthogonal views. The BH3 peptide binding groove enlarged in (B) is boxed. (B) Enlarged view of mutant N1 (coloured) superposed
on wild-type N1 (white) with the position of the mutated residue shown as sticks. A model of a bound BH3 peptide is shown as in Figure 1.
doi:10.1371/journal.ppat.1002430.g002
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terminus of N1 (Figure 6A). The chimeric protein (N1-w) was
expressed at similar levels to WT N1 (Figure 6B) and, like Bcl-w,
localised exclusively to mitochondria, whereas WT N1 had a
diffuse cytoplasmic localisation (Figure 6C) as seen previously [3].
However, N1-w was unable to protect cells from STS-induced
apoptosis, whereas both N1 and Bcl-w could do so (Figure 6D).
This suggests that N1 requires a cytosolic localisation to interfere
with cell death signalling.
Abolition of the N1 anti-NF-kB activity, but not the anti-
apoptotic activity, attenuates VACV virulence
Having identified N1 mutants displaying exclusively an anti-NF-
kB or anti-apoptotic phenotype, we generated recombinant
VACV in which these alleles were reinserted into a deletion
mutant lacking the N1L gene (vDN1) at the N1L gene natural locus
[3]. Viruses expressing N1 I6E (vN1.I6E), R58Y (vN1.R58Y), or
R71Y (vN1.R71Y) were constructed via transient dominant
selection (see Materials and Methods). The genomes of these
Figure 3. Biochemical and biophysical characterization of mutant N1. (A) Ability of FLAG-tagged WT and mutant N1 to immunoprecipitate
HA-tagged WT N1 after transfection in HEK 293T cells. (B) Ability of FLAG-tagged WT and mutant N1 to immunoprecipitate a renilla luciferase-fused
WT N1 (Rluc.N1). Relative fold binding for each plasmid is calculated in triplicates after normalization to empty vector (EV). Data are expressed as
means 6 SD with statistical analysis (Student’s t-test; ***P,0.0005). (C) Purification of WT and mutant N1 after over-expression in E. coli.( D) SEC-
MALS curves obtained for WT and mutant N1. Weight-averaged molar mass (dotted lines) is shown across the elution profile (A280 nm, solid lines) of
wild-type and mutant N1. While wild-type (WT) N1 and the groove-filling mutants elute as a dimer, I6E N1 is predominantly monomeric. (E) Ability of
mutant N1 proteins expressed from recombinant VACV viruses to dimerise in HEK 293 T-REx cells with TAP-tagged N1 expressed after addition of
doxycycline (Dx) for 2 h.
doi:10.1371/journal.ppat.1002430.g003
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N1L gene locus and the DNA sequence of these PCR products was
determined, confirming the presence of individual mutations and
no other changes. The ability of these viruses to replicate in cell
culture was characterised and there were no growth differences
compared to wild-type virus (data not shown), as would be
expected since no differences were observed between carefully
matched recombinant viruses with or without the N1L gene [3].
The expression of the N1 protein by these viruses was investigated
by immunoblotting of infected cell extracts and this showed that
Figure 4. Functional characterization of mutant N1. (A) Inhibition of apoptosis by measurement of mitochondrial dysfunction in cells
transfected with wild-type and mutant N1, after treatment with staurosporine (black bars) or mock-treated (white bars). (B) Inhibition of NF-kB
activation in cells co-transfected with reporter plasmids for NF-kB activity and TK-Rluc as internal control, together with 100 ng of the indicated
plasmids or pcDNA4/TO (EV). Cells were treated with IL-1b, lysed and the relative fold activation of NF-kB activity was determined. (C) Alternatively,
10 ng of FLAG-TRAF6 plasmid was included in the transfection mix to induce activation of the NF-kB reporter. Data is expressed as means 6 SD with
statistical analysis (Student’s t-test; *P,0.05; **P,0.005; ***P,0.0005).
doi:10.1371/journal.ppat.1002430.g004
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shown), as had been observed following transfection (Figure 3A
and Figure S1).
The mutant N1 viruses were then used to investigate the
contribution of N1-mediated anti-apoptotic activity or inhibition
of NF-kB activation to virulence. Groups of mice were infected
with the N1 mutant viruses by either the intradermal or intranasal
route and compared with wild-type virus and vDN1. In the
intradermal model, animals were inoculated with 10
4 plaque-
forming units (p.f.u.) in each ear and the size of the local lesions
formed was recorded daily (Figure 7A). Inoculation with vDN1
generated significantly smaller lesion sizes than the control wild-
type virus (vN1.WT) from days 6 to 25 post infection (p.i.).
However, infection with vN1.R58Y or vN1.R71Y induced lesions
that were indistinguishable from vN1.WT. In contrast, lesions
induced by vN1.I6E were smaller than those obtained for
vN1.WT (p,0.05 on days 6 to 25 p.i.) and were similar to those
induced by vDN1. To check the level of infection with these viruses
were equivalent, and to investigate if the mutant N1 proteins were
stable in vivo, the amount of N1 and a late structural protein, D8,
present within infected tissue 48 h p.i. was investigated by
immunoblotting. This showed that the levels of N1 and D8
expression were equivalent between the different viruses except for
vDN1, which produced no N1 as expected (Figure 7B). Therefore,
the different phenotypes observed in vivo between the N1 mutants
were not due to different levels of N1 protein.
In the intranasal infection model, inoculation with vDN1
induced less weight loss and reduced signs of illness compared
with vN1.WT, and these differences were significant from days 6
to 15 p.i. (Figure 8A and B). Inoculation with vN1.R58Y and
vN1.R71Y caused a similar outcome as vN1.WT, indicating these
mutations did not result in virus attenuation. Inoculation with
vN1.I6E, however, resulted in lower weight loss and reduced signs
of illness, similar to the loss observed in animals infected with
vDN1.
Collectively, vN1.I6E, but not vN1.R58Y or vN1.R71Y, was
attenuated in both murine models of infection. Considering that
R58Y N1 was no longer anti-apoptotic and I6E N1 no longer
displayed anti-NF-kB activity, our results indicate that suppression
of the N1 anti-apoptotic activity does not significantly attenuate
VACV virulence whilst suppression of NF-kB activation does.
Discussion
VACV protein N1 is an intracellular virulence factor that is
expressed early during infection and modulates innate immunity
by at least two strategies: preventing apoptosis and inhibiting NF-
kB activation [7,8,13]. In this study, structurally-informed
mutagenesis and functional analysis were used to identify distinct
regions of the N1 protein that are required for these different
activities, and, using recombinant viruses engineered to express N1
proteins that inhibit either apoptosis or NF-kB activation, the
relative contribution of these activities to virus virulence was
determined.
N1 is a Bcl-2-like protein that contains a surface groove [6,8]
similar to those in cellular anti-apoptotic Bcl-2 proteins that bind
the BH3 motif of pro-apoptotic Bcl-2 members [36,37]. Like other
cellular anti-apoptotic Bcl-2 proteins, N1 can also bind some pro-
apoptotic Bcl-2 proteins and BH3 peptides [6,8]. To determine if
N1 mediated its anti-apoptotic activity via the surface groove,
tyrosine residues were introduced into the groove by mutagenesis.
Protein crystallography showed that 2 of these mutations (R58Y
and Q61Y) placed the bulky aromatic side chain of the tyrosine
residue within the groove in a position likely to restrict access by
Figure 5. Immunoprecipitation of N1 mutants with cellular pro-apoptotic Bcl-2 proteins. (A) Ability of TAP-tagged WT and mutant N1 to
immunoprecipitate HA-tagged Bad after transfection in HEK 293T cells. FLAG-tagged N1 constructs were immunoprecipitated with anti-FLAG
antibody and presence of HA-tagged Bad was determined by anti-HA immunoblotting. (B) Ability of TAP-tagged WT and mutant N1 to
immunoprecipitate Bid after transfection in HEK 293T cells. TAP-tagged N1 constructs were affinity-purified (AP) using streptavidin beads and
presence of Bid was analysed by anti-Bid immunoblotting.
doi:10.1371/journal.ppat.1002430.g005
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unchanged from wild-type (Figure 2 and Figure S2). In contrast, a
R71Y mutation placed the tyrosine flat on the base of the groove.
Notably, the N1 mutants R58Y and Q61Y were unable to block
STS-induced apoptosis, whereas R71Y, wild-type N1 and also an
I6E mutant, which could no longer form dimers, did so
(Figure 4A). Consistent with this, WT N1 and mutant I6E and
R71Y all retain an open surface groove (Figure 2), bind Bid and
Bad (Figure 5), and inhibit apoptosis (Figure 4). In contrast,
mutant Q61Y which has an occluded surface groove (Figure 2) no
longer binds Bid or Bad (Figure 5) and no longer inhibits apoptosis
(Figure 4). Investigation of N1 mutant R58Y binding to Bid and
Bad was unsuccessful because this mutant bound strongly to all
proteins examined, including both pro-apoptotic and anti-
apoptotic Bcl-2 proteins and tubulin, for unknown reasons (data
not shown). In conclusion, the surface groove is critical for the
anti-apoptotic activity of N1 whereas dimer formation is not.
Programmed cell death requires the activation of Bax and Bak
(the pro-apoptotic effector proteins), which is proposed to occur by
one of two mechanisms: the ‘direct activation’ model, in which
BH3-only proteins directly interact with Bax and Bak [40], and the
‘indirect activation’ model, where the BH3-only proteins bind to
the anti-apoptotic Bcl-2 proteins inducing the release of Bax and
Bak [41]. Bak is a mitochondrial integral membrane protein and
binds Bcl-xL [42], but Bax is a soluble protein that requires
insertion to the OMM for activation and is normally held in the
cytoplasm by anti-apoptotic Bcl-2 members [43,44]. Data
presented here suggest that N1 exerts its anti-apoptotic function
in the cell cytoplasm, but not at the OMM (Figure 6), targeting
pro-apoptotic cellular BH3-only Bcl-2 proteins by virtue of its
BH3-binding groove (Figure 5). This strategy differs from those
reported for other viral anti-apoptotic proteins, such as VACV F1
or myxoma virus M11, that directly bind to mitochondrial-bound
Bak [28,31,32,33,45].
Figure 6. Mitochondrial targeting of N1 abolishes its anti-apoptotic function. (A) Addition of the mitochondrial-targeting C-terminus
domain from Bcl-w into N1 to generate N1-w. (B) Immunoblot showing the expression levels of WT N1 and N1-w in transfected cells. (C) Confocal
images showing localisation of N1, N1-w and Bcl-w after transfection into HeLa cells incubated with Mitotracker Red and stained with anti-N1 and
FITC-conjugated anti-rabbit antibody. (D) Mitochondrial dysfunction measurement in cells transfected with N1, N1-w and Bcl-w after treatment with
staurosporine (black bars) or mock-treated (white bars). Data are means 6 SD with statistical analysis (Student’s t-test; **P,0.005; ***P,0.0005).
doi:10.1371/journal.ppat.1002430.g006
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apoptotic proteins is its ability to also inhibit pro-inflammatory
signalling, particularly NF-kB activation [7,8,13]. In this study, we
have identified a mutation in N1 (I6E) that abolishes its ability to
form dimers (Figure 3) and its anti-NF-kB activity (Figure 4B and
4C), while retaining its anti-apoptotic potency (Figure 4A) and its
ability to bind Bid and Bad (Figure 5). An obvious conclusion
would be that dimerisation of N1 is required for its ability to block
NF-kB activation. However, in other viral and cellular Bcl-2
family proteins the surface equivalent to the N1 dimer interface,
formed by helices 1 and 6, has been implicated in binding partner
proteins [11,39,46]. In the case of B14, mutation of this surface
inhibited the ability of B14 to bind IKKb and block NF-kB
activation [11]. It is possible that the ‘1–6 face’ of N1 mediates its
binding to other proteins, and that dimerisation is driven by a
requirement to shield this hydrophobic protein:protein interaction
surface from polar solvents. Interestingly, I6E N1 was not
completely impaired for NF-kB inhibition and retained minimal
inhibitory activity when compared to control samples (Figure 4C).
VACV containing the I6E mutation on N1 (vN1.I6E) also was
slightly less attenuated than vDN1 (Figure 7 and 8). It is therefore
possible that while the I6E mutation significantly disrupted
dimerisation, it did not completely abolish N1 interaction with a
binding partner that mediates inhibition of NF-kB activation.
Confirmation of this will require identification of N1 binding
partners and understanding of the molecular mechanism by which
N1 inhibits the NF-kB pathway.
Deletion of the VACV N1L gene attenuates VACV virulence
[3,4,5,47]. To understand the mechanism underlying this
attenuation, we have analysed the virulence of VACVs expressing
an N1 protein with significantly reduced anti-apoptotic
(vN1.R58Y) properties, or anti-inflammatory properties (vN1.I6E),
or a protein retaining both activities (vN1.R71Y) and compared
these to WT VACV strain Western Reserve (vN1.WT) and a
deletion mutant lacking the N1L gene (vDN1). We only observed
an attenuated infection upon inoculation with vN1.I6E, which
resembled that of vDN1 (Figure 7 and 8). Mice infected with
Figure 7. Intradermal inoculation with vN1.I6E and vDN1, but
not vN1.R58Y and vN1.R71Y, attenuates VACV infection. (A)
Size of the lesions observed daily after infection of mice (groups of 5) by
intradermal injection of 10
4 p.f.u. of the indicated virus in each of the
ear pinnae. Data shown are the mean 6 standard error of the mean
(s.e.m.) of lesion sizes for each group of animals. The horizontal bar
indicates the days on which the lesion size caused by vDN1 and vN1.I6E
was statistically different from vN1.WT (P,0.05, Student’s t-test). (B)
Expression levels of WT and mutant N1 compared to VACV control
protein D8 in ear pinnae tissues after 48 h p.i.
doi:10.1371/journal.ppat.1002430.g007
Figure 8. Intranasal inoculation with vN1.I6E and vDN1, but not
vN1.R58Y and vN1.R71Y, attenuates VACV infection. (A) Weight
of mice (groups of 5) infected intranasally with 5610
3 p.f.u. of the
indicated virus. The mean weight of each group on each day is
expressed as ratio of the mean weight of the same group on day zero.
Data shown are the mean 6 s.e.m. of relative weight for each group of
animals. (B) Signs of illness recorded for every group according to an
arbitrary scale of 1 to 4 as described previously [62]. The horizontal bar
indicates the days on which the weight loss or the signs of illness
caused by vDN1 and vN1.I6E was statistically different from vN1.WT
(P,0.05, Student’s t-test). (C) Summary table of the biochemical
functions and in vivo virulence of the N1 alleles introduced into VACV
strain Western Reserve (WR) compared to wild-type (vN1.WT) and
deletion mutant (vDN1, [3]).
doi:10.1371/journal.ppat.1002430.g008
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the intranasal model and developed smaller lesions in the
intradermal model of infection. In contrast, vN1.R58Y and
vN1.R71Y were as virulent as vN1.WT, possibly because
apoptosis is inhibited by other VACV anti-apoptotic proteins
[31–33]. These results demonstrate that the virulence of VACV
WR is not increased by the anti-apoptotic activity of the N1
protein. Virulence is instead enhanced by the presence of N1
dimers and/or an intact N1 dimerisation interface facilitating
N1-mediated inhibition of NF-kB dependent inflammatory
signalling and potentially other (yet unknown) cellular signalling
pathways.
It is interesting that the inhibition of NF-kB activation by N1 is
so important for virulence while the virus expresses several other
proteins that inhibit NF-kB activation. There may be several
reasons for this but one important factor is likely to be the position
in the signalling pathway at which each virus inhibitor acts. For
instance, an inhibitor of TLR- and IL-1-induced NF-kB activation
could contribute to virulence differently to an inhibitor of TNF-
induced NF-kB activation, and be different again to an inhibitor,
like B14, that blocks all these pathways at the IKK complex [9].
Further, there is cross talk between signalling pathways and an
NF-kB inhibitor acting at the IKK complex would not inhibit
mitogen-activated protein kinase (MAPK) activation following
TNF stimulation, whereas an inhibitor acting at the TNF receptor
complex might do so.
The severe attenuation of VACV lacking N1 has been linked to
a stronger natural killer cell response and a modulation of CD69
+
cells [4], but also to a more robust intrapulmonary CD8
+ T cell
response [47]. More recently, Gratz et al. (2011) could only
observe disease caused by infection of an ectromelia virus (the
causative agent of mousepox) lacking the N1L gene after depletion
of both CD4
+ and CD8
+ T cells, thus linking N1 activity to
modulation of the T cell function [48]. While it seems that the
attenuation of vDN1 can be attributed to T cell function, an
immune response generated very early during the infection
precedes and determines this adaptive response. We show here
that pro-inflammatory signalling rather than the apoptotic
signalling pathway is crucial for the orchestration of the adaptive
immune response that leads to the clearance of vDN1. Presum-
ably, an NF-kB-dependent sensing of VACV infection induces a
robust production of pro-inflammatory cytokines and chemokines
that eventually modulate the adaptive response. Therefore, an NF-
kB-dependent immune activation is important for the control of
VACV infection.
In summary, we identified mutations at the surface groove and
the dimer interface of N1 that interrupt either its ability to inhibit
host-cell apoptosis or to inhibit the NF-kB pathway. This proves
that these two activities are distinct and mediated by discrete
regions of the protein surface. Only mutations that disrupt
inhibition of NF-kB activation lead to significant attenuation of
VACV following intranasal and intradermal infection in mice.
These results show that the ability of N1 to prevent apoptosis does
not contribute to VACV WR virulence in the models studied and
highlights the crucial role played by NF-kB in development of
immune responses against viral infection.
Material and Methods
Ethics statement
This work was carried out in accordance with regulations of
The Animals (Scientific Procedures) Act 1986. All procedures were
approved by the United Kingdom Home Office and carried out
under the Home Office project licence PPL 70/7116.
Expression plasmids and antibodies
pET24a-based bacterial expression plasmids containing C-
terminal His-tagged N1 and N1(C40S) (pET24a-N1 and pET24a-
N1-C40S respectively) were described previously [3,8]. A mamma-
lian expression plasmid of N1 incorporatinga C-terminalFLAGtag
was generated by PCR amplification of cDNA from pET24a-N1
using Platinum Taq HiFi DNA polymerase (Invitrogen) with
forward primer 59-CGCGAATTCGCCACCATGAGGACTC-
TACTTATTAGATATATTCTTG-39 (EcoRI site underlined)
and reverse primer 59- GCCTCTAGATTACTTATCGTCGT-
CATCCTTGTAATCTTTTTCACCATA-TAGATCAATCAT-
TAGATC -39 (XbaI site underlined) containing the FLAG
sequence. The PCR product was cloned into the tetracycline-
inducible expression vector pcDNA4/TO (Invitrogen) via EcoRI
and XbaI (Roche) restriction sites using T4 DNA ligase (Novagen)
to make pcDNA4/TO-N1-FLAG. Also, the N1 cDNA was cloned
into pcDNA4/TO incorporating a C-terminal HA tag. Alterna-
tively, the sequence of N1 was codon-optimised (coN1) for
expression in human cells (GENEART) and subcloned into
pcDNA4/TO as a fusion to C-terminal tandem-affinity purification
(TAP) tag containing 2 copies of the streptavidin-binding sequence
and 1 copy of the FLAG epitope [49].
The renilla luciferase (Rluc)-fused N1 expression vector was
generated by PCR amplification of N1 cDNA with forward primer
59-GGCTCATGAGGACTCTACTTATTAGA-39 (BspHI site
underlined) and reverse primer 59-GCAGCGGCCGCT-
TATTTTTCACCATATAGATC-39 (NotI site underlined). The
PCR product was cloned downstream the Rluc gene present in the
M5P vector (a gift from Dr. Felix Randow, MRC Laboratory of
Molecular Biology, Cambridge, United Kingdom, [50]) that had
been digested with PciI and NotI to generate an N-terminal
Rluc.N1 fusion.
The FLAG-tagged B14 expression plasmid was described
previously [51]. NF-kB luciferase reporter, pTK-renilla luciferase,
and FLAG-tagged TRAF6 were gifts from Dr. Andrew Bowie
(Trinity College, Dublin, Ireland). Bcl-xL was provided by
Professor Xin Lu (Ludwig Institute for Cancer Research, Oxford,
United Kingdom). CD20 plasmid was provided by Dr. Nick
Dyson (Charleston, USA). Anti-N1 [3], anti-D8 [52], anti-FLAG
(Sigma), anti-HA (Sigma), anti-Bid (Cell Signaling), anti-tubulin
(Millipore) and anti-actin (Sigma) antibodies were used to
determine protein expression levels.
Mutagenesis of N1
To construct an N1 mutant with a mitochondrial-targeting C-
terminal hydrophobic tail, a structure-based sequence alignment of
N1 and human Bcl-w was used to determine the additional tail
residues (G155-K193) present in Bcl-w but absent in N1. To
generate an N1/Bcl-w tail fusion product (N1-w), N1 was amplified
by PCR from pET24a-N1 Platinum Taq HiFi DNA polymerase
(Invitrogen) with the forward primer described above for generation
of pcDNA4/TO-N1-FLAG and reverse primer 59-CTC-
CTCCAGGGCTTTTTCACCATATAGATCAATCATTAG-39
(N1 sequence is underlined; Bcl-w sequence in bold). For the Bcl-w
tail, human mRNA was extracted from HeLa cells using an RNeasy
purification kit (Qiagen). Bcl-w cDNA was generated using
Superscript III reverse transcriptase (Invitrogen) according to the
manufacturer’s instructions and gene-specific reverse primer 59-
GCCTCTAGATCACTTGCTAGCAAAAAAGGCCCCTAC-39
(XbaI site is underlined; Bcl-w sequence is in bold; stop codon in
bold italic). The Bcl-w tail was amplified from the Bcl-w cDNA
using forward primer 59-TATGGTGAAAAAGCCCTGGAG-
GAGGCGCGGCGTC-39 (N1 sequence is underlined, Bcl-w
sequence is in bold) and the reverse primer used above for
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equimolar amounts of N1 and Bcl-w tail PCR products as
templates, purified using a QIAquick PCR purification kit (Qiagen).
The PCR was carried out using the forward primer used to
construct pcDNA4/TO-N1-FLAG and the reverse primer used for
generation of the Bcl-w tail PCR product. The resulting N1-w PCR
product was cloned into pcDNA4/TO (Invitrogen) via EcoRI and
XbaI (Roche) restriction sites using T4 DNA ligase (Novagen) to
make pcDNA4/TO-N1-w.
The N1 structure (PDB ID 2UXE) and a model of the structure
overlayed onto the M11:Bak BH3 peptide complex (PDB ID
2JBY) were used to design mutations to disrupt the N1 dimer and
fill the N1 BH3 surface groove. All mutations were introduced
into pET24a-N1(C40S), pcDNA4/TO-N1 and pcDNA4/TO-
coN1(C40S) vectors using the QuikChange site-directed muta-
genesis kit (Stratagene) and verified by DNA sequencing.
Purification, biophysical characterisation, crystallisation,
diffraction data collection and structure refinement
Wild-type and mutant N1 were over-expressed in E. coli and
purified as described previously [8]. The identities of purified wild-
type and mutant N1 were confirmed by mass spectroscopy (not
shown). Purified wild-type and mutant N1 were concentrated to
2.0–2.4 mg mL
21 and injected (100 mL) onto an analytical S75
Superdex 10/300 gel filtration column equilibrated in 50 mM
Tris, 150 mM NaCl, pH 8.5. Static light-scattering (DAWN
HELEOS II, Wyatt Technology), differential refractive index
(Optilab rEX, Wyatt Technology) and UV absorbance (280 nm;
Agilent 1200 UV, Agilent Techologies) of the eluate were recorded
inline and data were analysed using the ASTRA software package
(Wyatt Technology).
Purified mutant N1 was further concentrated to 15.4–19.7 mg
mL
21 in 50 mM Tris, 150 mM NaCl, pH 8.5 and crystallised in
sitting drops containing 100–200 nL of protein and 100 nL of
reservoir solution (R58Y: 2% w/v polyethylene glycol 3350, 15%
w/v Tacsimate pH 7.0, 100 mM HEPES pH 7.0; Q61Y and
R71Y: 19–21% PEG 1500, 76–85 mM MIB buffer system
(Molecular Dimensions) pH 7.0) equilibrated against 95 mL
reservoirs at 20.5uC. Crystals were cryoprotected by brief
immersion in reservoir solution supplemented with 20–25% v/v
glycerol before flash-cryocooling in a cold (100 K) N2 gas stream.
Diffraction data were recorded from cryocooled (100 K) crystals at
Diamond beam line I03 (R71Y) and ESRF beam lines ID23-2
(R58Y) or ID14-2 (Q61Y). Diffraction data were processed using
HKL2000.
Structures of N1 mutants were solved by isomorphous
difference fourier synthesis, using the high resolution structure of
N1 (PDB ID 2I39) [8] as a starting model. Structures were built
using COOT [53] and refined in BUSTER-TNT (Global Phasing)
using TLS and Local Structure Similarity Restraints [54]. The
refinement was informed by the MolProbity web server [55] and
the validation tools present in COOT. Structural superpositions
were performed using SSM [56] and molecular graphics were
prepared using PyMOL (DeLano Scientific).
Cells and viruses
BS-C-1, HeLa, HEK 293T and HEK 293 T-REx cells
(Invitrogen) were grown at 37uC in a 5% CO2 atmosphere in
Dulbecco’s modified Eagle’s medium (DMEM), or minimum
essential medium (MEM) for HeLa cells, supplemented with 10%
fetal bovine serum (FBS; Invitrogen), 4 mM L-glutamine (Invitro-
gen), 100 U mL
21 penicillin (Invitrogen) and 100 mg mL
21
streptomycin (Invitrogen). HeLa cells and HEK 293 T-REx cells
were also supplemented with MEM non-essential amino acid
solution (Sigma) and blasticidin (Invitrogen), respectively. A stable
cell line expressing TAP-tagged N1 in an inducible manner was
generated by transfection of a TAP-tagged N1 construct (see
section of expression plasmids) into HEK 293 T-REx cells. Clones
were selected in the presence of zeocin (Invitrogen) for over 2
weeks and expression of N1 was shown to be dependent upon
addition of doxycycline.
VACV recombinants vN1.WT and vDN1 derived from VACV
strain Western Reserve (WR) were described previously [3]. For
the generation of VACV recombinants expressing mutated N1
proteins, the mutations I6E, R58Y and R71Y were introduced by
using the QuikChange site-directed mutagenesis kit (Stratagene)
into a pUC13 plasmid containing the entire N1 open reading
frame and its left and right flanking regions in WR. This plasmid
allows transient dominant selection of the desired viruses by
expressing E. coli guanine xanthine phosphoribosyltransferase
(Ecogpt) as selectable marker [57,58]. All mutations were verified
by DNA sequencing. A pUC13-N1 plasmid containing the I6E,
the R58Y or the R71Y was then transfected separately into vDN1-
infected cells and mycophenolic acid-resistant viruses were isolated
by plaque assay. These viruses were subsequently resolved into
deletion virus (vDN1) or mutant viruses (vN1.I6E, vN1.R58Y,
vN1.R71Y) in the presence of 6-thioguanine as described [59].
Viruses were screened by PCR using primers located in the
flanking regions, and finally expanded and titrated by plaque assay
in BS-C-1 cells. Protein expression was analysed after infection of
BS-C-1 cells at 10 p.f.u. per cell for 6 h.
Immunoflourescence
HeLa cells were seeded on glass coverslips and transfected with
expression vectors for wild-type N1, N1-w or Bcl-w using
FugeneHD (Roche). Cells were incubated for 30 min with
Mitotracker Red (Invitrogen) diluted in MEM containing 2.5%
FBS. Cells were immediately fixed with 4% paraformaldehyde
(PFA) for 10 min on ice, washed with PBS and fixed again with
8% PFA for 20 min at room temperature. Cells were subsequently
quenched with 50 mM ammonium chloride, blocked with 5%
horse serum and permeabilised before staining with anti-N1 serum
and fluorescein isothiocyanate (FITC)-conjugated anti-rabbit
antibody (Invitrogen).
Apoptosis assay
Apoptosis assays were carried out as described previously [7,8].
Briefly, HeLa cells were transfected with expression vectors for
FLAG-tagged Bcl-xL, wild-type or mutant I6E, R58Y, Q61Y, and
R71Y N1, or empty vector (EV) pcDNA4/TO together with a
plasmid encoding CD20 surface marker using FugeneHD (Roche).
Cells were stimulated with 0.5 mM staurosporine for 1 h or left
untreated as indicated. The level of apoptosis was assessed by
measuring the change in mitochondrial potential (Dym) using the
potentiometric dye JC-1. Cells were collected, washed in
phosphate-buffered saline (PBS) and stained with anti-CD20
APC antibody (BD Pharmingen) for 20 min on ice for detection of
transfected cells. Then cells were stained with 2 mM JC-1 dye
(Invitrogen) for 30 min at 37uC, washed in PBS, re-suspended in
FACS buffer (PBS with 2% (v/v) FBS) and analysed by flow
cytometry (FACScan; Becton Dickinson). Three independent
experiments were performed in triplicates. Data are expressed as
means 6 standard deviation (SD) with statistical analysis
(Student’s t-test; **P,0.005; ***P,0.0005).
Reporter gene assays
HEK 293T cells were seeded in 96-well plates and transfected
with 100 ng of the indicated expression vectors or pcDNA4/TO
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and 10 ng of pTK-renilla luciferase as internal control, using
Fugene6 (Roche). After 24 h, the NF-kB-dependent gene
expression was induced by addition of 20 ng mL
21 of IL-1b
(Peprotech) diluted in DMEM supplemented with 2% FCS.
Alternatively, 10 ng of FLAG-tagged TRAF6 plasmid was added
into the transfection mix. Cells were then washed once with ice-
cold PBS and harvested in passive lysis buffer (Promega). A ratio of
firefly:renilla luciferase activity was calculated for every condition
and normalized to that of the corresponding unstimulated control
to determine the relative fold stimulation of NF-kB activity. At
least two experiments were performed in triplicate. Data are
expressed as means 6 SD with statistical analysis (Student’s t-test;
*P,0.05; **P,0.005; ***P,0.0005).
Immunoprecipitation and LUMIER
For immunoprecipitation, HEK 293T cells were transfected
with a pcDNA4/TO expressing HA-tagged N1 and either TAP-
tagged WT or mutant I6E, R58Y, Q61Y, R71Y N1, or empty
vector (pcDNA4/TO) using the calcium chloride precipitation
method [60]. After 24 h, cells were washed once with ice-cold PBS
and lysed with IP buffer (10% glycerol, 150 mM NaCl, 20 mM
Tris-HCl [pH 7.4], 0.1% Triton-X100, and protease inhibitors
[Roche]). Post-nuclear supernatants were incubated with FLAG
agarose (Sigma) for 2 h at 4uC. After 3 washes with ice-cold Tris
buffered saline (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM
KCl, TBS), the beads were boiled in the presence of sample buffer
and analysed by immunoblotting. For immunoprecipitation of
pro-apoptotic Bcl-2 proteins, the same conditions were used after
lysis of cells with an NP-40-based lysis buffer as described in
Cooray et al. [8]. Proteins were fractionated and transferred to
nitrocellulose membranes (Amersham), blocked for 1 h at room
temperature with 5% skimmed milk (Sigma) and incubated with
primary antibody overnight at 4uC. The next day, membranes
were washed 3 times with PBS containing 0.1% Tween (PBST),
incubated with horseradish peroxidase (HRP)-conjugated second-
ary antibody, washed again with PBST, and finally incubated with
chemiluminesence reagent (Amersham) to detect immunoreactive
bands.
For LUMIER [61], cells were transfected with the same
plasmids, but the HA-tagged N1 was replaced by Rluc.N1. After
washing the beads with TBS, beads were incubated with FLAG
peptide (Sigma) diluted at 150 mgm L
21 in Passive Lysis Buffer
(Promega) for 1 h at 4uC. The luciferase activity was measured
both in the eluates and the whole cell lysates, and these ratios
compared to the ratio of a control reaction were plotted. Data
shown are from one out of two independent experiments
performed in triplicate. Data are expressed as means 6 SD with
statistical analysis (Student’s t-test; ***P,0.0005).
In vivo experiments
The virulence of the recombinant VACVs was analysed in two
mouse infection models. In the intranasal model, groups of 5
BALB/C mice 6–8 weeks old were inoculated with 5610
3 p.f.u. of
the different recombinant virus in 20 mL PBS. Mice were weighed
daily and signs of illness were recorded as described previously
[62]. In the intradermal model, groups of 5 C57BL/6 mice were
inoculated with 10
4 p.f.u. in 10 mL PBS in both left and right ear
pinnae [63]. The size of the lesions in infected ears was monitored
daily with the aid of an electronic digital caliper. To determine
protein expression levels in tissues after infection, infected ear
tissue was collected 48 h p.i., disrupted in 10% (w/v) PBS and
centrifuged 500 x g for 5 min. Cells were lysed in 0.1 mL of IP
buffer and post-nuclear supernatants were treated with benzonase
(125 U). Proteins were finally fractionated and analysed by
immunoblotting.
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Figure S1 Immunoblotting of WT and mutant N1
proteins expressed in HeLa cells.
(TIF)
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